Phase 4 psychedelic research trials
Data as of 31 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Phase 4 is a registry phase value. Studies of an intervention that is already approved for some use, run to learn more about its use in practice. A phase describes how a study is designed, not what it found.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 67 registered studies are counted on this page.
Which substances
Counts per substance hub. Ketamine is limited to studies classified as psychiatric research, and records about disease-modifying therapy that match the abbreviation DMT are removed.
| Substance hub | Studies |
|---|---|
| Ketamine | 67 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 9 | 13% |
| Not yet recruiting | 2 | 3% |
| Enrolling by invitation | 1 | 1% |
| Active, not recruiting | 3 | 4% |
| Completed | 30 | 45% |
| Terminated | 6 | 9% |
| Suspended | 1 | 1% |
| Withdrawn | 3 | 4% |
| Status not reported | 12 | 18% |
Countries
Country is taken from the study's linked research site. 6 of 67 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 33 | 49% |
| Canada | 6 | 9% |
| Australia | 3 | 4% |
| China | 3 | 4% |
| Türkiye | 3 | 4% |
| Brazil | 2 | 3% |
| Germany | 2 | 3% |
| Egypt | 2 | 3% |
| United Kingdom | 2 | 3% |
| Israel | 2 | 3% |
Registry-listed start years
| Start year | Studies |
|---|---|
| 2024 and later | 10 |
| 2020 to 2023 | 23 |
| 2015 to 2019 | 18 |
| 2010 to 2014 | 11 |
| Before 2010 | 5 |
Study design
- 67 interventional and 0 observational studies.
- Median planned or actual enrolment is 48 participants (range 1 to 1,806, across 64 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Depression and mood | 40 |
| Suicidal thoughts | 11 |
| Pain and headache | 2 |
| Trauma and PTSD | 1 |
| Anxiety | 1 |
| Other substance use | 1 |
| Cancer and end of life | 1 |
| Healthy volunteers | 1 |
Latest registry-listed start dates
The 25 studies with the latest start dates, newest first. Dates may be estimated, including future dates; a listed date does not confirm that a study started. The order is not a ranking. Each ID links to its own ClinicalTrials.gov record.
| Registry ID | Title as registered | Status | Phase | Country | Registry dates |
|---|---|---|---|---|---|
| NCT07680140 | Biomarker-Guided Antidepressant Selection | Recruiting | Phase 4 | United States | Source start: 2026-08-10 (actual) Saved start 2026-07-01 differs from reported 2026-08-10; the saved day is not established by this observation. Source date detailsStart: 2026-08-10 (precision: day; source type: ACTUAL; actual) Primary completion: 2028-09 (precision: month; source type: ESTIMATED; estimated) Study completion: 2028-12 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.880Z; registry revision: 2026-09-23 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT07139106 | Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts | Not yet recruiting | Phase 4 | United States | Source start: 2026-10-01 (estimated) Saved start 2026-02-01 differs from reported 2026-10-01; the saved day is not established by this observation. Source date detailsStart: 2026-10-01 (precision: day; source type: ESTIMATED; estimated) Primary completion: 2028-10-01 (precision: day; source type: ESTIMATED; estimated) Study completion: 2028-10-01 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.160Z; registry revision: 2026-08-03 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT07369102 | Esketamine With or Without Integration Therapy for Treatment-Resistant Depression | Recruiting | Phase 4 | Puerto Rico | Source start: 2026-02-01 (estimated)Source date detailsStart: 2026-02-01 (precision: day; source type: ESTIMATED; estimated) Primary completion: 2026-12-01 (precision: day; source type: ESTIMATED; estimated) Study completion: 2026-12-01 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.483Z; registry revision: 2026-01-27 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT07120477 | Esketamine Versus Crisis Response Planning Versus Optimized Treatment as Usual for Suicide Prevention: A Pragmatic Controlled Trial in Two Brazilian Cities | Recruiting | Phase 4 | Brazil | Source start: 2026-06-01 (actual) Saved start 2026-01-01 differs from reported 2026-06-01; the saved day is not established by this observation. Source date detailsStart: 2026-06-01 (precision: day; source type: ACTUAL; actual) Primary completion: 2028-12 (precision: month; source type: ESTIMATED; estimated) Study completion: 2029-12 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.160Z; registry revision: 2026-09-16 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT06968624 | Ketamine for Postherpetic Neuralgia With Depression | Not yet recruiting | Phase 4 | Not reported | Source start: 2025-06-15 (estimated)Source date detailsStart: 2025-06-15 (precision: day; source type: ESTIMATED; estimated) Primary completion: 2026-04-01 (precision: day; source type: ESTIMATED; estimated) Study completion: 2026-06-01 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.089Z; registry revision: 2025-06-03 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT07053345 | A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression | Completed | Phase 4 | South Korea | Source start: 2025-06-09 (actual)Source date detailsStart: 2025-06-09 (precision: day; source type: ACTUAL; actual) Primary completion: 2026-07-13 (precision: day; source type: ACTUAL; actual) Study completion: 2026-07-13 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:18.089Z; registry revision: 2026-08-03 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT06414356 | The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD | Recruiting | Phase 4 | United States | Source start: 2024-10-02 (actual)Source date detailsStart: 2024-10-02 (precision: day; source type: ACTUAL; actual) Primary completion: 2025-04 (precision: month; source type: ESTIMATED; estimated) Study completion: 2027-05 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.400Z; registry revision: 2025-02-25 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT06278779 | Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression | Recruiting | Phase 4 | Australia | Source start: 2024-06-03 (actual)Source date detailsStart: 2024-06-03 (precision: day; source type: ACTUAL; actual) Primary completion: 2027-04 (precision: month; source type: ESTIMATED; estimated) Study completion: 2027-04 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.349Z; registry revision: 2026-05-29 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT06077487 | Ketamine-assisted Therapy for Advanced GI Cancer | Terminated | Phase 4 | United States | Source start: 2024-05-17 (actual)Source date detailsStart: 2024-05-17 (precision: day; source type: ACTUAL; actual) Primary completion: 2025-01-31 (precision: day; source type: ACTUAL; actual) Study completion: 2025-01-31 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:17.019Z; registry revision: 2025-05-21 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT06213324 | Neural Circuit Effects of Ketamine in Depression | Recruiting | Phase 4 | United States | Source start: 2024-01-31 (actual)Source date detailsStart: 2024-01-31 (precision: day; source type: ACTUAL; actual) Primary completion: 2028-03-30 (precision: day; source type: ESTIMATED; estimated) Study completion: 2028-04-30 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.349Z; registry revision: 2025-07-03 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT06103760 | Positioning of Esketamine Treatment in the Real-world Management of Depression | Recruiting | Phase 4 | Australia | Source start: 2023-10-31 (actual)Source date detailsStart: 2023-10-31 (precision: day; source type: ACTUAL; actual) Primary completion: 2027-12-15 (precision: day; source type: ESTIMATED; estimated) Study completion: 2028-08-15 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.019Z; registry revision: 2026-08-12 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT06060210 | Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion | Completed | Phase 4 | Egypt | Source start: 2023-10-29 (actual)Source date detailsStart: 2023-10-29 (precision: day; source type: ACTUAL; actual) Primary completion: 2025-09-01 (precision: day; source type: ACTUAL; actual) Study completion: 2025-11-01 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:17.019Z; registry revision: 2026-01-08 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT05554627 | VA Aripiprazole vs Esketamine for Treatment Resistant Depression | Withdrawn | Phase 4 | United States | Source start: 2023-10-27 (actual)Source date detailsStart: 2023-10-27 (precision: day; source type: ACTUAL; actual) Primary completion: 2023-10-27 (precision: day; source type: ACTUAL; actual) Study completion: 2023-10-27 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:16.599Z; registry revision: 2024-01-05 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT06034821 | Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan | Enrolling by invitation | Phase 4 | United States, Canada | Source start: 2023-10-01 (actual)Source date detailsStart: 2023-10-01 (precision: day; source type: ACTUAL; actual) Primary completion: 2030-10-01 (precision: day; source type: ESTIMATED; estimated) Study completion: 2030-12-01 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.019Z; registry revision: 2025-12-15 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT05698394 | Effect of Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth | Active, not recruiting | Phase 4 | China | Source start: 2023-09-09 (actual)Source date detailsStart: 2023-09-09 (precision: day; source type: ACTUAL; actual) Primary completion: 2025-10 (precision: month; source type: ESTIMATED; estimated) Study completion: 2025-11 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:16.639Z; registry revision: 2024-12-05 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT05997134 | Three Regimens of Ketamine Infusion in Complex Regional Pain Syndrome | Status not reported | Phase 4 | Egypt | Source start: 2023-08-30 (actual)Source date detailsStart: 2023-08-30 (precision: day; source type: ACTUAL; actual) Primary completion: 2024-09-01 (precision: day; source type: ESTIMATED; estimated) Study completion: 2024-09-01 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:16.980Z; registry revision: 2023-08-31 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT05506462 | An EEG Study of Intravenous Ketamine for Major Depression Disorder | Status not reported | Phase 4 | Not reported | Source start: 2023-01 (estimated) Saved start 2023-01-01 differs from reported 2023-01; the saved day is not established by this observation. Source date detailsStart: 2023-01 (precision: month; source type: ESTIMATED; estimated) Primary completion: 2024-01 (precision: month; source type: ESTIMATED; estimated) Study completion: 2024-02 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:16.599Z; registry revision: 2022-08-22 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT05615948 | Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression | Completed | Phase 4 | United States | Source start: 2022-12-06 (actual)Source date detailsStart: 2022-12-06 (precision: day; source type: ACTUAL; actual) Primary completion: 2024-05-17 (precision: day; source type: ACTUAL; actual) Study completion: 2024-05-17 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:16.599Z; registry revision: 2026-04-21 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT05655754 | Comparison of Esketamine/Propofol and Methohexital Anesthesia for ECT | Completed | Phase 4 | Austria | Source start: 2022-11-01 (actual)Source date detailsStart: 2022-11-01 (precision: day; source type: ACTUAL; actual) Primary completion: 2026-03-31 (precision: day; source type: ACTUAL; actual) Study completion: 2026-03-31 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:16.599Z; registry revision: 2026-10-07 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT05450432 | Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | Recruiting | Phase 4 | United States | Source start: 2022-10-13 (actual)Source date detailsStart: 2022-10-13 (precision: day; source type: ACTUAL; actual) Primary completion: 2026-06-01 (precision: day; source type: ESTIMATED; estimated) Study completion: 2026-06-01 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:16.239Z; registry revision: 2025-12-12 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT05487885 | Anhedonia, Development, and Emotions: Phenotyping and Therapeutics | Completed | Phase 4 | United States | Source start: 2022-07-22 (actual)Source date detailsStart: 2022-07-22 (precision: day; source type: ACTUAL; actual) Primary completion: 2024-12-19 (precision: day; source type: ACTUAL; actual) Study completion: 2025-06-01 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:16.599Z; registry revision: 2026-03-17 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT05950711 | Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study | Active, not recruiting | Phase 4 | United States | Source start: 2022-03-30 (actual)Source date detailsStart: 2022-03-30 (precision: day; source type: ACTUAL; actual) Primary completion: 2026-11-30 (precision: day; source type: ESTIMATED; estimated) Study completion: 2026-11-30 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:16.980Z; registry revision: 2025-08-11 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT05045378 | Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression | Completed | Phase 4 | Taiwan | Source start: 2022-03-15 (actual)Source date detailsStart: 2022-03-15 (precision: day; source type: ACTUAL; actual) Primary completion: 2024-11-30 (precision: day; source type: ACTUAL; actual) Study completion: 2024-11-30 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:15.858Z; registry revision: 2025-09-05 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT05026203 | Effectiveness of Ketamine Treatment for Three Consecutive Days in Depression | Completed | Phase 4 | Thailand | Source start: 2021-09-01 (actual)Source date detailsStart: 2021-09-01 (precision: day; source type: ACTUAL; actual) Primary completion: 2022-07-31 (precision: day; source type: ACTUAL; actual) Study completion: 2023-11-30 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:15.858Z; registry revision: 2024-03-15 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
| NCT04829318 | A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment | Completed | Phase 4 | Taiwan, Türkiye, Poland, Czechia, Germany, Greece, Finland, South Korea, Bulgaria, Hungary, Argentina, South Africa, Malaysia, Belgium | Source start: 2021-04-26 (actual)Source date detailsStart: 2021-04-26 (precision: day; source type: ACTUAL; actual) Primary completion: 2024-07-22 (precision: day; source type: ACTUAL; actual) Study completion: 2024-07-22 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:15.827Z; registry revision: 2025-09-18 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. |
Other substance hubs
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Enrolling by invitation | Completed | Terminated | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase not applicable